1.
|
Phase: Phase III Type: Treatment Status: Closed Age: 20 to 75 Sponsor: Other Protocol IDs: JCOG-0205-MF, C000000193, NCT00190515
|
|
2.
|
Phase: Phase III Type: Treatment Status: Closed Age: 20 to 75 Sponsor: Other Protocol IDs: YCU-BRI-HN-05-01, NCT00336947
|
|
3.
|
Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Protocol IDs: EORTC-16964G
|
|
4.
|
Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Protocol IDs: EORTC-16966C
|
|
5.
|
Phase: Phase II Type: Treatment Status: Completed Age: 75 and over Sponsor: NCI Protocol IDs: E-1299, NCT00004860, E1299
|
|
6.
|
Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: NU-99B3, BMS-NU-99B3, NU-DRUG-BMS-ORZEL, NCI-G00-1741, NCT00005608
|
|
7.
|
Phase: Phase II Type: Treatment Status: Closed Age: 18 to 79 Sponsor: Other Protocol IDs: BMS-200604, UMCC 0110g, NCT00037089
|
|
8.
|
Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EMR200025-001, NCT00439517
|
|
9.
|
Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MSKCC-96025, BMS-MSKCC-96025, NCI-V96-0942, NCT00002801
|
|
10.
|
Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: WSU-D-1641, WSU-04-28-98-M02-FB, NCI-G99-1526, NCT00003925
|
|
11.
|
Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: PCI-98013, PCI-IRB-990923, NCI-G00-1902, NCT00009815
|
|
12.
|
Phase: Phase I Type: Treatment Status: Completed Age: Over 18 Sponsor: NCI Protocol IDs: PCI-98012, PCI-IRB-990929, NCI-G00-1903, NCT00009828
|